Roche Drops Emugrobart In SMA And Lifts Scholar Rock’s Prospects
Underwhelming efficacy led to the myostatin inhibitor's discontinuation of in SMA and FSHD, but Roche will continue a separate study in obesity. Meanwhile, Scholar Rock’s rival apitegromab could soon be back on track for approval.
Scrip - March 20, 2026

Pipeline Watch: Seven Approvals And Eight Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - March 20, 2026

InflaRx Survival Hopes Rest On Izicopan
The German biotech hopes to start Phase IIb trials soon of the oral complement C5a inhibitor in the extremely competitive hidradenitis suppurativa market.
Scrip - March 20, 2026

Novartis Makes $3bn Bet On Synnovation’s PI3K? Inhibitor SNV4818
The deal, which is expected to close in the first half of 2026, includes $2bn upfront plus $1bn in milestone related payments.
Scrip - March 20, 2026

Natco’s 90% Cut Price Semaglutide Generic Sounds War Bugle In India
Natco has announced a 90% difference in the price of its semaglutide generic in multi-dose vials versus originator Novo Nordisk’s Ozempic pen ahead of launch tomorrow as Novo’s patents on the product expire today. Its pen will be 70% cheaper.
Scrip - March 20, 2026

NICE To Reassess English Funding Rejections Of Leqembi And Kisunla After Successful Appeals
According to the health technology assessment institute, NICE, new cost-effectiveness thresholds – which are higher than those that applied when the original decisions were made – will apply when its committee reconsiders the appraisals for Eisai and Eli Lilly’s Alzheimer’s disease drugs.
Pink Sheet - March 20, 2026

MEPs Vote To Delay And Simplify AI Act Rules For Medical Devices
In an effort to streamline AI rules for high-risk systems and improve competitiveness, two European Parliament committees agreed amendments to the EU AI Act that will allow medtech companies to avoid double certification with notified bodies. A plenary vote takes place in late March.
Medtech Insight - March 20, 2026

Four Validation Pillars Frame US FDA’s New Approach Methodologies For Rx And OTC Drugs
Context of use, human biological relevance, technical characterization and fitness for purpose are the key elements in validating novel methods to replace animal testing, the FDA said in a new draft guidance.
HBW Insight - March 19, 2026

K-Beauty Influence: Bioré Sees South Korea As ‘Springboard,’ Ulta Builds Korean Brand Portfolio
Kao Corp. will launch Bioré in South Korea, while promoting the brand’s UV products with a global campaign featuring K-Pop band Stray Kids. Separately, Ulta Marketplace adds 17 K-Beauty Brands to the K-Beauty World platform.
HBW Insight - March 19, 2026

Spanish Consumers Embrace Self-Care But Barriers Remain
A new ANEFP survey shows that while most Spanish consumers see self-care as essential to good health, gaps in knowledge, mental health support and broader socio?economic pressures continue to limit how effectively it is practised.
HBW Insight - March 19, 2026

California EPR Stakeholder Reports Due May 31 Will Shape Fees Under Program
Circular Action Alliance, the Producer Responsibility Organization in charge of implementing California’s EPR program, urges single-use packaging producers to comply with an upcoming May 31 deadline, which will shape proposed fees.
HBW Insight - March 19, 2026

Natco’s 90% Semaglutide Discount Sets Price Expectations In India
Natco has announced a 90% difference in the price of its semaglutide generic in multi-dose vials versus originator Novo Nordisk’s Ozempic pen ahead of launch tomorrow, as Novo’s patents on the product expire today. Its pen will be 70% cheaper.
Generics Bulletin - March 20, 2026

Iran War Could Threaten Long-Term Industry Sustainability
Amid “significant uncertainty” for the off-patent industry caused by the war in Iran, the IGBA has warned that a prolonged conflict “could make solvent supply a critical concern” while escalating costs and squeezed margins could affect the long-term sustainability of affordable medicines.
Generics Bulletin - March 20, 2026

Alvotech Pivots To Dual Sourcing Amid Regulatory Reset
Alvotech is shifting toward dual-source manufacturing and operational execution as it addresses FDA setbacks, expands its biosimilar pipeline and drives growth through global launches, with US approvals representing key upside to its 2026 outlook.
Generics Bulletin - March 20, 2026

Formycon Unlocks Global Markets For Its Eylea Biosimilar
Formycon expects its aflibercept biosimilar to enter European markets from the end of spring, as commercial paths also open up in Latin America and Asia Pacific countries.
Generics Bulletin - March 20, 2026

Execs On The Move: February 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - March 18, 2026

Adapt To Survive: Private Hospitals In A High-Pressure Landscape
Payers' and patients' growing preference for outpatient care is increasing pressure on private providers to continually reassess how they deliver value. Jean-Philippe Grosmaitre and Guillaume Duparc, partners at L.E.K. Consulting, outlined growth opportunities available to private hospitals.
In Vivo - March 18, 2026

An Irregular Regulatory Agency: Industry Contends With An Unpredictable FDA
A series of surprise rejections has made for an FDA that drug and vaccine manufacturers are finding much harder to read than in years past.
In Vivo - March 18, 2026